Potential cost to patient safety as NZ debates access to medicinal cannabis

Cannabis-based products will be allowed to bypass usual processes required for medicines in New Zealand and go directly onto the market without any proof of safety or effectiveness. Written by Michelle Glass and John Ashton of the University of Otago